Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Portfolio Pulse from Benzinga Insights
Ionis Pharmaceuticals (NASDAQ: IONS) has received mixed analyst ratings over the past three months, with 3 bullish and 3 somewhat bullish ratings. The average 12-month price target has decreased by 3.3% to $68.17. Analysts have maintained, raised, or lowered their ratings based on recent developments. Ionis faces revenue challenges with a decline of -8.45% over the past three months, and its financial metrics such as ROE, ROA, and debt-to-equity ratio indicate potential financial difficulties.
June 03, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ionis Pharmaceuticals has received mixed analyst ratings with a slight decrease in the average price target. The company faces revenue challenges and financial difficulties, as indicated by its ROE, ROA, and debt-to-equity ratio.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on the stock price. However, the company's revenue challenges and financial difficulties could weigh on investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100